ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,295.72
0.41%
Dow Jones
44,296.51
0.97%
Gold vs US Dollar
2,671.77
-1.60%
Brent Oil
74.225
-0.73%
Bitcoin
98,702.74
0.68%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Centessa Pharmaceuticals PLC (CNTA)

  7. Centessa Pharmaceuticals PLC (CNTA) News

Centessa Pharmaceuticals (CNTA)

Centessa Pharmaceuticals PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CNTA
DateTimeSourceHeadlineSymbolCompany
22/11/202422:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
22/11/202421:03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
21/11/202421:33Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
20/11/202421:03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
15/11/202421:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
12/11/202412:16Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CNTACentessa Pharmaceuticals PLC
12/11/202412:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTACentessa Pharmaceuticals PLC
12/11/202412:00GlobeNewswire Inc.Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business UpdateNASDAQ:CNTACentessa Pharmaceuticals PLC
04/11/202412:30GlobeNewswire Inc.Centessa Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:CNTACentessa Pharmaceuticals PLC
23/10/202421:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
23/10/202420:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
22/10/202420:15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
21/10/202420:55Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
18/10/202420:01Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:CNTACentessa Pharmaceuticals PLC
02/10/202420:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
02/10/202420:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
02/10/202420:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
02/10/202420:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
26/09/202410:00GlobeNewswire Inc.Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)NASDAQ:CNTACentessa Pharmaceuticals PLC
20/09/202420:55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
20/09/202420:01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
13/09/202420:02Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CNTACentessa Pharmaceuticals PLC
13/09/202420:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTACentessa Pharmaceuticals PLC
13/09/202402:34GlobeNewswire Inc.Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary SharesNASDAQ:CNTACentessa Pharmaceuticals PLC
13/09/202400:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
11/09/202420:40Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CNTACentessa Pharmaceuticals PLC
11/09/202420:04GlobeNewswire Inc.Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary SharesNASDAQ:CNTACentessa Pharmaceuticals PLC
11/09/202420:01Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:CNTACentessa Pharmaceuticals PLC
10/09/202420:06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:CNTACentessa Pharmaceuticals PLC
10/09/202411:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CNTACentessa Pharmaceuticals PLC
 Showing the most relevant articles for your search:NASDAQ:CNTA

Your Recent History

NYSE
ARE
Alexandria Real Estate E...
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    BLACK FRIDAY

    ADVFN

    Celebrating 25 years Est 1999-2024

    Save up to 60%* for Silver

    1 year 40%, 2 years 50% and *3 years 60%

    *Across 3 years £903.96 only 361.58